Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
8.05/14.38
|
|
Enterprise Value
42.88B
|
| Balance Sheet |
|
Book Value Per Share
37.27
|
| Cash Flow |
|
Cash Flow Yield
0.09
|
| Income Statement |
|
Total Revenue
16.31B
|
|
Operating Revenue Per Share
89.01
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry,and it serves biopharmaceutical firms, providers, payers, and policymakers. |

173.35 
